AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04121221
Drug: GA Depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
Trial: NCT01426815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
Trial: NCT00942136
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
Trial: NCT00942136
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
Trial: NCT00942136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Suspension as a single dose.
Trial: NCT04397341
Drug: docetaxel, cisplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly Induction regimen with Docetaxel, Cisplatin and Fluorouracil
Trial: NCT00169299
Drug: Multibotanical preparation + dietary soy counseling
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05742022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg orally 2 times a day, for 12 weeks
Trial: NCT04970940
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
Trial: NCT04970940
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
Trial: NCT02218463
Drug: Estradiol cream 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Trial: NCT01413854
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg, two times daily (oral adm.) during four weeks
Trial: NCT00879112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04443192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ZF874
Trial: NCT01359098
Drug: Ciprodex Otic Suspension
RxNorm normalized name: Ciprodex Otic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 gtt b.i.d. for 7 days.
Trial: NCT01359098
Drug: Ciprodexa Otic Foam
RxNorm normalized name: Ciprodex Otic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
Trial: NCT02893540
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: we are going to compare two maintenance treatment models with capecitabine in this study
Trial: NCT01075776
Drug: C-type natriuretic peptide (CNP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 pmol/min for 15 minutes intra-arterially
Trial: NCT01075776
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Trial: NCT00941551
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: levothyroxine 75-125 ug/day
Trial: NCT00941551
Drug: no levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observation only without prophylactic levothyroxine
Trial: NCT00390715
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03261635
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
Trial: NCT02620189
Drug: Anti-TNF Biologics Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00336921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT06204185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel consist of drug without the active component.
Trial: NCT01427907
Drug: Calcium acetate oral solution (COS)
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium Phosphate (DB11348)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
Trial: NCT00502281
Drug: highly purified urinary FSH
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01719926
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
Trial: NCT00479947
Drug: Probiotics (Natural product)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00479947
Drug: Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00044538
Drug: BAY59-8862 (Cytotoxic Taxane)
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose over 60 minutes every 3 weeks
Trial: NCT05455944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two identical placebo capsules is administered orally to patients
Trial: NCT02634255
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02266485
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00123552
Drug: Artemether+Lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to \< 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; \>35 kg:4 tabs per dose
Trial: NCT03446001
Drug: TRx0237 16 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TRx0237 4-mg tablets administered twice daily
Trial: NCT02266485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03446001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
Trial: NCT04166890
Drug: Articaine / EPINEPHrine Cartridge
RxNorm normalized name: articaine / epinephrine Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
Trial: NCT02125240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet three times daily by mouth
Trial: NCT03446001
Drug: TRx0237 8 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TRx0237 4-mg tablet administered twice daily
Trial: NCT00003650
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003650
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003650
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01097785
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg, P.O.,daily for 30 days
Trial: NCT01097785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily for 30 days
Trial: NCT00118833
Drug: Hypericum perforatum (St. John's wort)
RxNorm normalized name: HYPERICUM PERFORATUM (ST. JOHN'S WORT)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03165929
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral flurbiprofen spray
Trial: NCT03165929
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo spray
Trial: NCT01449565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
Trial: NCT00709189
Drug: Norgestimate/Ehinyl Estradiol; Folic acid.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02592824
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
Trial: NCT00701233
Drug: Corticosteroid injection into Carpal Tunnel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
Trial: NCT05535036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received 2ml of intravenous saline solution
Trial: NCT04128917
Drug: RAPAE01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAPAE01/Clarithromycin/Amoxicillin BID peroral
Trial: NCT02118285
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
Trial: NCT02118285
Drug: INCB024360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
Trial: NCT02240680
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching linagliptin 5 mg
Trial: NCT02034435
Drug: Epleronone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg daily
Trial: NCT00553423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30 ml q6hrly for 48 hrs
Trial: NCT01382550
Drug: long-lasting OAT or 12-month OAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (\>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded.
Trial: NCT03498261
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00988195
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weeks 13-24 (once every 3 weeks)
Trial: NCT03019185
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing an inert placebo
Trial: NCT00250679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nebule or placebo aerolizer
Trial: NCT00624923
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
Trial: NCT00624923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Trial: NCT02653937
Drug: Tsumura's shigyakusan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne
Trial: NCT02556060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dosing schedule as study drug
Trial: NCT02698969
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes
Trial: NCT03835117
Drug: Wide-spectrum nutritional supplement
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Trial: NCT01749904
Drug: BOL-303259-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
Trial: NCT01166087
Drug: Fluoxetine Hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Trial: NCT03230487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 - single rising dose. Part 2 multiple rising dose
Trial: NCT04685226
Drug: ICP-723
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-723 is a white, round, uncoated table
Trial: NCT02303574
Drug: AZD7986, oral solution, 1 to 50 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose in single ascending dose part: 5 mg
Trial: NCT01697787
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
Trial: NCT02244632
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV injection every second week for 8 weeks.
Trial: NCT01873677
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01873677
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01606189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
Trial: NCT00908856
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
Trial: NCT01218802
Drug: Rosuvastatin 10 mg. daily for 96 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
Trial: NCT01218802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will take a sugar pill daily for 96 weeks
Trial: NCT00515164
Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
RxNorm normalized name: REDUCTIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL Hydrogel
Trial: NCT01041859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= tablet, route= oral use. Matching placebo twice daily.
Trial: NCT01952652
Drug: Group N:Naproxen sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug will be given 60 minutes before surgery
Trial: NCT01952652
Drug: Group NC :naproxen sodium codeine phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug will be given 60 minutes before surgery
Trial: NCT01354938
Drug: Clarithromycin modified release 500 mg
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
Trial: NCT01167023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 30 days.
Trial: NCT03451162
Drug: DHES0815A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Trial: NCT00609765
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5
Trial: NCT00609765
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1
Trial: NCT00410384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Trial: NCT00634062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
Trial: NCT02462265
Drug: Oshadi D & Oshadi R;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;
Trial: NCT00429702
Drug: Decadron®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00429702
Drug: Benadryl®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00309517
Drug: Fluourouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00309517
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00312143
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01880827
Drug: MMS
RxNorm normalized name: Cystemms-V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow and volume after meal solution
Trial: NCT00086671
Drug: ABT-874/Human monoclonal antibody against IL-12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00086671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00843362
Drug: Dinoprostone vaginal pessary
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg controlled-release dinoprostone pessary applied for 24 hours
Trial: NCT00843362
Drug: Dinoprostone vaginal gel
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
Trial: NCT04700319
Drug: CD19/CD20 CAR-T cell infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once
Trial: NCT00602901
Drug: Usual medical care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
Trial: NCT00201747
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.